RICCIUTI, BIAGIO
 Distribuzione geografica
Continente #
NA - Nord America 1.004
AS - Asia 749
EU - Europa 586
SA - Sud America 84
AF - Africa 21
OC - Oceania 2
Totale 2.446
Nazione #
US - Stati Uniti d'America 972
SG - Singapore 371
IE - Irlanda 137
CN - Cina 131
IT - Italia 90
RU - Federazione Russa 81
VN - Vietnam 79
HK - Hong Kong 74
DE - Germania 70
BR - Brasile 62
FR - Francia 58
FI - Finlandia 37
RO - Romania 27
CA - Canada 23
GB - Regno Unito 23
IN - India 18
BD - Bangladesh 12
JP - Giappone 11
KR - Corea 10
PL - Polonia 9
SE - Svezia 9
AR - Argentina 8
AT - Austria 7
CH - Svizzera 7
MX - Messico 7
IQ - Iraq 6
UA - Ucraina 6
ES - Italia 5
MA - Marocco 5
UZ - Uzbekistan 5
VE - Venezuela 5
GR - Grecia 4
LT - Lituania 4
OM - Oman 4
TR - Turchia 4
ZA - Sudafrica 4
CL - Cile 3
EC - Ecuador 3
EG - Egitto 3
ET - Etiopia 3
NL - Olanda 3
AZ - Azerbaigian 2
BE - Belgio 2
BH - Bahrain 2
BO - Bolivia 2
ID - Indonesia 2
IL - Israele 2
JO - Giordania 2
NG - Nigeria 2
NP - Nepal 2
PH - Filippine 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
DK - Danimarca 1
DZ - Algeria 1
GA - Gabon 1
HU - Ungheria 1
KH - Cambogia 1
KI - Kiribati 1
KZ - Kazakistan 1
LS - Lesotho 1
ME - Montenegro 1
MR - Mauritania 1
MT - Malta 1
PK - Pakistan 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
Totale 2.446
Città #
Singapore 280
Chandler 179
Dublin 137
San Jose 98
Hong Kong 74
Ashburn 60
San Mateo 57
Beijing 39
Boardman 36
Dong Ket 33
Santa Clara 33
Altamura 31
Moscow 31
Munich 29
Bucharest 27
Lawrence 27
Medford 27
Princeton 27
Lauterbourg 22
Los Angeles 21
Helsinki 20
Wilmington 19
Perugia 18
Ho Chi Minh City 15
New York 15
Frankfurt am Main 14
Des Moines 12
Hanoi 10
Ottawa 10
Seoul 10
Tokyo 10
San Paolo di Civitate 9
The Dalles 9
Ann Arbor 8
Andover 7
Brooklyn 7
Saint Petersburg 7
São Paulo 7
Turku 7
Warsaw 7
Falkenstein 6
Nuremberg 6
Poplar 6
San Francisco 6
Stockholm 6
Denver 5
Montreal 5
Norwalk 5
Phoenix 5
Redwood City 5
Seattle 5
Arezzo 4
Dhaka 4
Manchester 4
Nanjing 4
Orem 4
Rome 4
Toronto 4
Atlanta 3
Baghdad 3
Caracas 3
Chicago 3
Houston 3
Johannesburg 3
Mexico City 3
Mumbai 3
Muscat 3
Paris 3
Redmond 3
Vienna 3
Amman 2
Amsterdam 2
Ankara 2
Brussels 2
Calgary 2
Chennai 2
City of London 2
Cleveland 2
Columbus 2
Council Bluffs 2
Erbil 2
Faenza 2
Guayaquil 2
Hải Dương 2
Kanpur 2
Manama 2
Nazrēt 2
New Delhi 2
Norfolk 2
Oklahoma City 2
Rio de Janeiro 2
San Miniato Basso 2
Simi Valley 2
São José do Rio Preto 2
Tashkent 2
Terni 2
Tianjin 2
Tân Bình 2
Vilnius 2
Zurich 2
Totale 1.673
Nome #
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 120
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 119
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 113
Antibody–drug conjugates for lung cancer in the era of personalized oncology 110
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 108
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 108
Non-coding RNAs in lung cancer 104
Osimertinib 98
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 98
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 96
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 92
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 91
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 90
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 89
Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications 89
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 89
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 84
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 82
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 82
High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art 82
Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy 77
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 76
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 76
High density lipoprotein cholesterol and cancer: Marker or causative? 76
Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking 74
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 73
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 72
Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy 64
Totale 2.532
Categoria #
all - tutte 12.064
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.064


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 0 0 0 0 0 0 0 0 33
2021/2022201 1 38 1 3 3 3 3 55 4 22 28 40
2022/2023530 28 104 12 39 47 56 0 29 189 0 22 4
2023/2024199 11 26 19 4 2 1 38 1 15 6 43 33
2024/2025369 9 30 36 16 44 19 7 26 73 26 53 30
2025/2026980 51 67 41 111 178 90 176 55 90 94 18 9
Totale 2.532